Recent analysis reveals that Eli Lilly and Novo Nordisk lead in AI citation shares, despite AbbVie and Johnson & Johnson being the largest advertisers in U.S. drug marketing. This emerging trend highlights a shift in focus towards digital engagement and the use of artificial intelligence in pharmaceutical marketing strategies. The report suggests that while traditional direct-to-consumer (DTC) spending remains significant, the growing prominence of AI in citations indicates a potential evolution in how companies are prioritizing their marketing efforts.
The implications of this shift are profound for B2B professionals across regulatory, QA/QC, CMC, sourcing, and portfolio management sectors. As AI-driven insights become more integral to marketing, companies may need to reassess their spending strategies and consider the long-term value of organic citations versus traditional advertising. This could lead to a more data-driven approach in the industry, fostering innovation and potentially reshaping competitive dynamics.
Open the full market picture for your next decision →
